Mr. Hugh Rogers reports

BIONXT ANNOUNCES ENHANCED SUBLINGUAL PRODUCT DEVELOPMENT PIPELINE WITH INNOVATIVE SOLUTIONS FOR AUTOIMMUNE DISEASES AND LONGEVITY

Bionxt Solutions Inc. has expanded its next-generation product pipeline. This includes proprietary sublingual (thin-film), transdermal (skin patch) and oral (enteric-coated tablet) drug delivery systems targeting autoimmune diseases such as multiple sclerosis (MS), myasthenia gravis (MG), lupus nephritis (LN) and rheumatoid arthritis (RA), as well as an exciting initiative in the fast-growing longevity market. These advancements highlight Bionxt's commitment to developing innovative, patient-centric solutions to improve compliance, enhance drug bioavailability and address critical unmet medical needs.

Pipeline highlights

1. Bionxt lead product BNT23001 -- multiple sclerosis (MS)

Bionxt's lead pipeline product for MS is a proprietary sublingual (thin-film) formulation of Cladribine, offering an innovative alternative to traditional oral tablets. This next-generation delivery system is designed to overcome the challenges of swallowing difficulty, a common issue among MS patients, while enhancing drug absorption and compliance.

Cladribine tablets are currently approved in over 75 countries and achieved sales exceeding $1-billion (U.S.) in 2023 (Merck KGaA). With the global MS drug market projected to exceed $41-billion (U.S.) by 2033 (Market.us), Bionxt's sublingual (thin-film) product offers a unique, patient-friendly approach.

2. Bionxt BNT23001 -- myasthenia gravis (MG)

Building on its MS expertise, Bionxt is repurposing its sublingual (thin-film) Cladribine technology for myasthenia gravis, a chronic neuromuscular condition that causes muscle weakness and fatigue. Patients with MG often face difficulty swallowing, making Bionxt's sublingual delivery system an ideal solution. The global MG market is anticipated to reach $6.7-billion (U.S.) by 2032 (Clinical Trials Arena).

3. Bionxt BNT24002 -- lupus nephritis (LN)

Bionxt is developing a proprietary sublingual (thin-film) product for lupus nephritis, a serious autoimmune condition that can lead to kidney failure. This innovative drug delivery system focuses on maximizing bioavailability while minimizing side effects, addressing a critical gap in the LN treatment market, which is expected to grow to $3.2-billion (U.S.) by 2032.

4. Bionxt BNT24003 -- rheumatoid arthritis (RA)

Rheumatoid arthritis is a prevalent autoimmune condition affecting millions globally, causing joint pain, swelling and reduced mobility. Bionxt is leveraging its expertise in sublingual (thin-film) and oral (enteric-coated tablet) technologies to develop proprietary solutions that improve compliance and therapeutic outcomes. The global RA drug market is projected to surpass $27-billion (U.S.) by 2033 (Precedence Research).

5. Bionxt BNT24004 -- formulation for longevity and anti-aging

Bionxt is also entering the booming longevity and anti-aging sector, projected to reach $93-billion (U.S.) by 2027 (Statista). The company is advancing proprietary sublingual (thin-film) and oral (enteric-coated tablet) drug products with active pharmaceutical ingredients that show early-stage evidence of benefits such as slowing ovarian aging, extending fertility and promoting healthy aging. These innovative solutions are tailored to meet the growing demand for effective anti-aging therapies.

Bionxt drug delivery system -- advancing health with precision medicine

Bionxt's proprietary drug delivery system -- sublingual (thin-film), transdermal (skin patch) and oral (enteric-coated tablet) -- represents a significant step forward in improving therapeutic outcomes. By focusing on next-generation technologies, Bionxt is delivering patient-friendly solutions that prioritize convenience, precision and bioavailability across a range of major high-growth therapeutic markets.

"Our expanded pipeline showcases Bionxt's leadership in next-generation drug delivery," said Hugh Rogers, chief executive officer of Bionxt Solutions. "With innovative solutions like sublingual (thin-film), transdermal (skin patch) and oral (enteric-coated tablet) systems, we're addressing unmet needs in critical markets, improving patient outcomes and driving long-term growth opportunities for Bionxt."

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin-film), transdermal (skin patch) and oral (enteric-coated tablet) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity. With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, initially focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and on the OTC (over-the-counter) markets under the symbol BNXTF; and it trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.